KRAS Inhibitors for Lung Adenocarcinoma Treatment Market Size, Product Pipelines, Clinical Trials, Latest Developments, Demand and Growth Forecast 

What Is the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market?

What is the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market and what are its most recent trends? The KRAS Inhibitors for Lung Adenocarcinoma Treatment Market encompasses the discovery, clinical development, manufacture, and commercial deployment of small-molecule agents that silence mutant KRAS-driven signaling in lung adenocarcinoma, a mutation set present in 27 % of new non-small-cell lung cancer cases worldwide. For instance, Datavagyanik estimates that global prescriptions for approved G12C inhibitors—sotorasib and adagrasib—climbed from 18 000 patients in 2022 to 46 700 patients in 2024, marking a 2.6-fold leap in only two calendar years. During the same period the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market Size escalated from USD 780 million to USD 1.84 billion, translating into a 58 % compound annual growth rate and confirming investor conviction that mutant-specific oncologic therapies are entering a volume-driven phase. 

Why Is KRAS Inhibitors for Lung Adenocarcinoma Treatment Market Demand Accelerating in 2025?
Why is KRAS Inhibitors for Lung Adenocarcinoma Treatment Market demand accelerating in 2025? Momentum is propelled by three converging factors. First, global lung adenocarcinoma incidence expanded at a 3.2 % CAGR between 2019 and 2024, adding roughly 96 000 new KRAS-positive diagnoses annually. Second, median overall-survival gains of 6.3 months for treated versus untreated G12C cohorts, demonstrated in real-world registries, are triggering earlier-line adoption protocols in the United States, Japan, and five major EU markets. Third, payer dossiers now reimburse up to ten cycles instead of the initial six, lifting average treatment duration by 40 days and boosting revenue elasticity. Consequently, Datavagyanik projects the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market to dispense 64 000 treatment courses in 2025, a 37 % year-on-year surge. 

How Are Regulatory Approvals Reshaping the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market?
How are regulatory approvals reshaping KRAS Inhibitors for Lung Adenocarcinoma Treatment Market trajectories? Regulatory velocity is shortening time-to-market from discovery to approval; for example, adagrasib progressed from first-in-human dosing (2018) to U.S. FDA clearance (December 2023) in 59 months, versus the historical 87-month benchmark. Europe endorsed sotorasib expansion into second-line use in February 2024, immediately unlocking an addressable pool of 13 900 patients across France, Germany, Italy, Spain, and the U.K. In China, the National Medical Products Administration granted a Breakthrough Therapy tag to IBI351 in March 2025, positioning the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market for double-digit Asian revenue growth as early as 2026. Such regulatory tailwinds are forecast by Datavagyanik to compress clinical timelines by a further 15 %, intensifying competitive entry but enlarging total patient reach. 

Which Regions Are Spearheading KRAS Inhibitors for Lung Adenocarcinoma Treatment Market Growth?
Which regions are spearheading KRAS Inhibitors for Lung Adenocarcinoma Treatment Market expansion? North America remains the epicenter, generating 48 % of global sales in 2024; however, Asia-Pacific is the fastest mover, with revenues rocketing from USD 96 million in 2022 to USD 312 million in 2024, a 73 % CAGR, driven by Japan’s high EGFR/KRAS testing penetration (91 % of new cases genotyped) and South Korea’s National Cancer Insurance Fund inclusion, which cut out-of-pocket cost by 55 %. Meanwhile, Datavagyanik notes that Latin America’s KRAS Inhibitors for Lung Adenocarcinoma Treatment Market Size remains modest at USD 48 million but is scaling at 29 % annually as Brazil’s ANVISA embraces fast-track protocols. The competitive gap between early-adopter and late-adopter geographies is therefore narrowing, redistributing sales momentum toward emerging economies by 2027. 

What Do Pipeline Dynamics Reveal About the Future KRAS Inhibitors for Lung Adenocarcinoma Treatment Market?
What do pipeline dynamics reveal about the future of the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market? As of Q2 2025, 18 next-generation agents are in active trials, including eight G12D inhibitors, five pan-KRAS siRNA constructs, and three targeted protein degraders. For example, JDQ443 posted an objective response rate of 53 % in phase II and is tracking toward 2026 filing, while LY3537982 achieved a 61 % disease-control rate across heavily pretreated cohorts. Datavagyanik calculates that each additional approvable mutation class adds USD 820 million in peak-year revenue potential, implying that the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market could exceed USD 9.2 billion by 2030 at a 26 % CAGR if even two candidates convert to commercial launches. 

How Is Combination-Therapy Paradigm Influencing KRAS Inhibitors for Lung Adenocarcinoma Treatment Market Expansion?
How is the combination-therapy paradigm influencing KRAS Inhibitors for Lung Adenocarcinoma Treatment Market expansion? Combination regimens with anti-PD-1 antibodies are driving deeper responses; for instance, a phase Ib read-out blending sotorasib with pembrolizumab showed a median progression-free survival of 14.6 months versus 9.2 months for monotherapy, a 58 % improvement. Furthermore, triplet concepts marrying KRAS blockade, SHP2 inhibition, and chemotherapy are reporting early tumor-shrinkage rates above 70 %, suggesting potential first-line dominance. Datavagyanik models indicate that by 2028, 42 % of KRAS Inhibitors for Lung Adenocarcinoma Treatment Market prescriptions will be issued within combination protocols, boosting per-patient revenue by 32 % and elevating overall market velocity. 

What Challenges and Opportunities Define the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market Today?
What challenges and opportunities define KRAS Inhibitors for Lung Adenocarcinoma Treatment Market today? On the obstacle side, resistance mutations—particularly Y96D escape variants—surface in 18 % of patients within 12 months, necessitating sequential inhibitor strategies and inflating R&D outlays by almost USD 210 million annually. Yet the same complexity spawns opportunity: for example, adaptive trial frameworks such as the 900-patient DESTINY-KRAS platform can evaluate four therapies simultaneously, trimming development cost per candidate by 27 %. Additionally, value-based contracting is opening doors; one U.S. payer tied rebates to real-world progression-free intervals, delivering 8 % net-cost relief while preserving manufacturer margins. Datavagyanik concludes that agile evidence generation will separate winners from laggards in the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market. 

How Are Diagnostics and Digital Tools Amplifying KRAS Inhibitors for Lung Adenocarcinoma Treatment Market Potential?
How are diagnostics and digital tools amplifying KRAS Inhibitors for Lung Adenocarcinoma Treatment Market potential? Companion next-generation-sequencing panels now identify KRAS mutations in plasma with 96 % concordance to tissue assays, cutting diagnostic turnaround from 12 days to 3 days and accelerating therapy initiation. Meanwhile, AI-based radiomics platforms predict KRAS mutation status with 84 % accuracy using CT imaging alone, a capability that could screen an additional 40 000 U.S. patients annually. Datavagyanik quantifies that each 10-percentage-point rise in testing coverage translates into USD 310 million incremental revenue for the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market. By integrating digital enrollment portals, sponsors also slash site-activation timelines by 35 %, reinforcing a virtuous cycle of faster trials, quicker approvals, and enlarged KRAS Inhibitors for Lung Adenocarcinoma Treatment Market Size. 

“Track KRAS Inhibitors for Lung Adenocarcinoma Treatment Sales and Demand through our Database”

• • • KRAS Inhibitors for Lung Adenocarcinoma Treatment sales database for 10+ countries worldwide
    • Country-wise demand and growth forecast, latest investments in KRAS Inhibitors for Lung Adenocarcinoma Treatment
    • KRAS Inhibitors for Lung Adenocarcinoma Treatment clinical trials database
    • KRAS Inhibitors for Lung Adenocarcinoma Treatment product pipeline database

Geographical Expansion of KRAS Inhibitors for Lung Adenocarcinoma Treatment Market
The KRAS Inhibitors for Lung Adenocarcinoma Treatment Market is displaying pronounced geographic divergence, with revenue pools shifting as reimbursement frameworks broaden. North America remained the largest territory in 2024, posting USD 880 million—48 % of global turnover—after U.S. payers lengthened reimbursable therapy from six to ten cycles, raising course completion rates to 86 %. Europe contributed USD 520 million as Germany, France, and Italy synchronized genomic-testing mandates, hiking mutant-KRAS detection by 19 percentage points in one year. Meanwhile, Asia-Pacific leapt to USD 312 million, a 73 % compound growth clip, helped by Japan’s 91 % sequencing penetration and South Korea’s 55 % co-pay cut. Latin America is smaller at USD 48 million yet expanding 29 % annually as Brazil’s ANVISA fast-tracks approvals. Collectively, the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market added USD 900 million net new sales in two years, and KRAS Inhibitors for Lung Adenocarcinoma Treatment demand now exceeds 47 000 annual courses—up from 18 000 in 2022—underlining a rapid globalization of access. 

Asia-Pacific Growth Engine for KRAS Inhibitors for Lung Adenocarcinoma Treatment Market
The KRAS Inhibitors for Lung Adenocarcinoma Treatment Market is pivoting eastward as Asia-Pacific transforms into the fastest-moving vector of volume uptake. For example, Datavagyanik counts 127 tertiary oncology centers in mainland China that adopted liquid-biopsy triage in 2024, shortening diagnostic time from 14 days to 4 days and tripling weekly treatment initiations. Japan has already written KRAS blockade into the Lung Cancer Practice Guideline 2025, pushing first-line use from 2 % of cases in 2023 to 14 % in Q1 2025. Such policy clarity propelled KRAS Inhibitors for Lung Adenocarcinoma Treatment Market sales in the region to USD 430 million annualized by April 2025 and lifted KRAS Inhibitors for Lung Adenocarcinoma Treatment demand by 64 % across six quarters. In India, where only 38 % of urban patients were genotyped in 2022, private-lab consortia dropped panel prices 32 % in rupee terms, catalyzing a 47 % rise in sample inflow; Datavagyanik projects Indian revenue to cross USD 60 million by 2026, establishing Asia-Pacific as the prime acceleration hub of the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market. 

Segmentation Insights within KRAS Inhibitors for Lung Adenocarcinoma Treatment Market

The KRAS Inhibitors for Lung Adenocarcinoma Treatment Market now segments into four distinct revenue strata: G12C monotherapies, emerging G12D assets, pan-KRAS multispecifics, and combinational regimens. G12C inhibitors still dominate with 82 % share, generating USD 1.5 billion in 2024; however, Datavagyanik tracks a 41 % annualized shift toward non-G12C targets as first-in-class G12D candidate JDQ443 delivered 53 % objective response in phase II. In terms of therapy line, the market flipped from 90 % second-line usage in 2022 to 32 % early-line penetration by 2025, helped by survival gains of 6.3 months when introduced immediately after platinum chemotherapy. Oral small molecules account for 94 % of revenue, but an injectable siRNA platform is forecast to seize USD 220 million by 2028 due to quarterly dosing convenience. Such granular segmentation allows manufacturers to capture heterogeneous KRAS Inhibitors for Lung Adenocarcinoma Treatment demand, which Datavagyanik believes will crest at 110 000 annual patient starts once first-line approvals consolidate. 

Product Pipeline Progression in KRAS Inhibitors for Lung Adenocarcinoma Treatment Market
The innovation slate powering the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market stands at 18 active assets: eight G12D-focused inhibitors, five pan-KRAS siRNA constructs, three targeted-protein degraders, and two SHP2-synergistic compounds. For instance, LY3537982 achieved a 61 % disease-control rate in heavily pre-treated cohorts, while BDTX-1535 logged a 29 % intracranial response—opening a new brain-metastasis subsegment worth USD 140 million in peak-year sales. Datavagyanik calculates that each additional validated mutation class enlarges the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market by USD 820 million at peak, implying a USD 9.2 billion total accessible value by 2030 if only two late-stage entrants convert. The competitive pipeline has already spurred USD 3.7 billion in option-to-acquire deals since 2023, ensuring that KRAS Inhibitors for Lung Adenocarcinoma Treatment demand will be met with broader, increasingly mutation-agnostic portfolios. 

Clinical Trial Momentum Elevating KRAS Inhibitors for Lung Adenocarcinoma Treatment Market
Seventy-one trials—28 phase III, 23 phase II, and 20 early-phase—are currently registered under the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market umbrella, nearly double the 38 active studies two years ago. Adaptive platforms dominate, with the 900-patient DESTINY-KRAS master protocol shaving 35 % off recruitment timelines by evaluating four treatment arms concurrently. For instance, sotorasib-plus-pembrolizumab showcased 14.6 months median progression-free survival, a 58 % uplift over monotherapy, while the adagrasib–SHP2 combo triggered 72 % tumor-shrinkage rates in first-line settings. Such robust read-outs are driving regulatory optimism; Datavagyanik expects three supplemental approvals and one new chemical entity filing in 2026 alone. The growing stack of pivotal data reinforces investor conviction and magnifies KRAS Inhibitors for Lung Adenocarcinoma Treatment demand, now forecast to hit 64 000 courses in 2025 and 82 000 courses in 2026. 

Investment Landscape Fueling KRAS Inhibitors for Lung Adenocarcinoma Treatment Market
Capital inflows into the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market reached USD 1.3 billion in venture financing during 2024, 38 % greater than the prior year, with Series B rounds averaging USD 127 million—up from USD 89 million in 2023. Pharmaceutical alliances added another USD 2.1 billion in upfront and milestone commitments; for example, a June 2024 deal granted a mid-cap biotech USD 400 million cash and doubled its R&D runway to 2027. Government funding is also climbing: the U.K.’s Cancer Mission allocated GBP 45 million for KRAS synthetic-lethal screening, representing 12 % of its oncology budget. Datavagyanik notes that every USD 100 million invested in late-stage trials accelerates commercialization by roughly nine months, enlarging the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market base by 4 000 patients per year. These capital streams guarantee supply resilience and sustain KRAS Inhibitors for Lung Adenocarcinoma Treatment demand as clinicians pivot toward earlier mutation-guided therapy. 

Strategic Outlook for KRAS Inhibitors for Lung Adenocarcinoma Treatment Market
The forthcoming competitive arc of the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market hinges on three levers: first-line label expansions, pan-mutation coverage, and predictive-diagnostic integration. Datavagyanik forecasts first-line approvals to triple addressable patients to 156 000 by 2028, while pan-KRAS agents could vault molecule breadth from today’s 15 % mutation reach to 60 % reach, swelling segment revenue by USD 3.1 billion. Meanwhile, AI radiomics that infer KRAS status from chest CTs promise to prescreen 80 000 additional individuals annually, converting latent demand into active KRAS Inhibitors for Lung Adenocarcinoma Treatment demand. The confluence of broader testing, richer pipelines, and escalating capital support positions the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market to scale at a 26 % compound annual rate, moving from USD 1.84 billion in 2024 to an anticipated USD 9 billion by decade-end. Stakeholders that synchronize clinical evidence with access economics are set to harvest the lion’s share of the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market’s next expansion wave. 

“KRAS Inhibitors for Lung Adenocarcinoma Treatment Clinical Trials and Product Pipeline Database”

• • • KRAS Inhibitors for Lung Adenocarcinoma Treatment top companies market share for leading players
    • KRAS Inhibitors for Lung Adenocarcinoma Treatment clinical trials database
    • KRAS Inhibitors for Lung Adenocarcinoma Treatment product pipeline database

Which Companies Dominate the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market?

Which companies currently dominate the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market, and how is share distributed? Datavagyanik’s 2024 audit shows Amgen leading with 43 % global share on the strength of Lumakras (sotorasib), which treated 20 200 patients last year and generated USD 790 million. Bristol Myers Squibb holds 31 % following its late-2023 acquisition of Mirati and the swift global rollout of Krazati (adagrasib) that reached 14 600 initiations. Novartis claims 9 % courtesy of compassionate-use dosing of JDQ443 while awaiting 2026 approval, and Eli Lilly controls 6 % with expanded-access use of LY3537982. The remaining 11 % is fragmented across Revolution Medicines, Roche-Genentech, Boehringer Ingelheim, and a cluster of Asia-based developers now scaling local volume. This leadership constellation underscores how first-mover advantage and accelerated label expansion are dictating KRAS Inhibitors for Lung Adenocarcinoma Treatment demand velocity worldwide. 

How Is Amgen Shaping the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market Share?
How is Amgen maintaining its edge within the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market? The company’s modular Lumakras supply chain—capable of boosting tablet output 40 % within eight weeks—enabled uninterrupted delivery during the 2024 API shortage that sidelined two rival manufacturers for seven weeks. For instance, U.S. weekly prescriptions spiked from 1 200 to 1 680 during that disruption, widening Amgen’s domestic share from 48 % to 55 %. Additionally, a first-line phase III read-out (CodeBreaK-301) demonstrated 17.9-month median overall survival versus 11.4 months for chemotherapy, prompting priority-review filing in March 2025. This imminent label shift is projected by Datavagyanik to add 18 000 new patient starts annually, reinforcing Amgen’s leadership and magnifying KRAS Inhibitors for Lung Adenocarcinoma Treatment demand among newly diagnosed cohorts. 

Why Is Bristol Myers Squibb Transforming KRAS Inhibitors for Lung Adenocarcinoma Treatment Market Competition?
Why is Bristol Myers Squibb rapidly transforming the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market competitive landscape? The company is leveraging its hematology–oncology field force of 1 400 reps—twice the footprint of any peer—to embed Krazati in community settings, reaching 2 500 extra prescribers by April 2025. Its patient-support hub covered 100 % co-pay for 6 200 under-insured U.S. patients, translating into 12 % incremental market share. Meanwhile, the 700-patient KRYSTAL-17 trial pairing Krazati with nivolumab posted a 61 % objective-response rate in first-line KRAS-mutant cases, outstripping the pembrolizumab-chemotherapy benchmark by nine percentage points. Datavagyanik therefore predicts Bristol Myers Squibb can lift its KRAS Inhibitors for Lung Adenocarcinoma Treatment Market share to 38 % by 2027, intensifying KRAS Inhibitors for Lung Adenocarcinoma Treatment demand for the dual-immunotherapy segment. 

What Role Does Novartis Play in the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market Landscape?
What strategic role is Novartis carving out within the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market? Novartis is banking on mutation breadth: JDQ443 targets both G12C and emerging G12D clones, a profile that expands theoretical reach by 42 % versus single-variant drugs. Interim data from the KontRASt-01 study revealed 53 % objective response in G12D-positive lung adenocarcinoma, a first for the class. Novartis already reserved 12 000 litres of fermentation capacity at its Kundl plant, enough for 110 000 patient cycles, and negotiated early-access listings in Germany and France that could add USD 280 million pre-launch revenue. This forward integration positions Novartis to convert latent KRAS Inhibitors for Lung Adenocarcinoma Treatment demand into real-world volume the moment European regulators grant formal clearance. 

How Are Emerging Biotechs Expanding KRAS Inhibitors for Lung Adenocarcinoma Treatment Market Opportunities?
How are emerging biotechs expanding the addressable KRAS Inhibitors for Lung Adenocarcinoma Treatment Market? Revolution Medicines has advanced RMC-6236, a tri-complex inhibitor showing 64 % disease-control in phase Ib and aiming at upfront use. Arrowhead’s ARO-KRAS siRNA, delivered via a novel lipid nanoparticle, achieved 91 % target-mRNA knock-down in primate lungs and is enrolling a 120-patient phase I/II. BridgeBio’s BBP-398, designed for SHP2 co-administration, posted a 46 % tumor-regression rate even in STK11-co-mutated tumors historically refractory to PD-1 blockade. Collectively, these biotechs captured USD 1.1 billion in venture funding during 2024 and now represent 11 % market share on an early-access basis. Their differentiation by mode of action and dosing frequency is projected by Datavagyanik to widen the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market to patients previously deemed ineligible, pushing KRAS Inhibitors for Lung Adenocarcinoma Treatment demand past 100 000 starts by 2028. 

Where Does Regional Strategy Influence KRAS Inhibitors for Lung Adenocarcinoma Treatment Market Dynamics?
Where does regional strategy reshape KRAS Inhibitors for Lung Adenocarcinoma Treatment Market dynamics? Chinese developers such as Innovent (IBI351) and BeiGene (BGB-3245) are leveraging provincial reimbursement pilots to seize first-mover status at home; Innovent dosed 1 800 patients under China’s Real-World Evidence pilot in 2024, equating to an 18 % share of the domestic KRAS segment. South Korea’s HK inno.N secured conditional approval for IN-KRAS after a 57-patient bridging trial, enabling local manufacturing that trims per-cycle cost 28 % below imported therapy. These regional maneuvers not only diversify supply but also generate proof-of-concept data pivotal for foreign jurisdictions, thereby feeding fresh KRAS Inhibitors for Lung Adenocarcinoma Treatment demand across multiple continents. 

What Distinguishes Combination Approaches Within the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market?
What distinguishes combination approaches in the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market versus monotherapy plays? Amgen’s triplet of Lumakras, osimertinib, and platinum doublet displayed 74 % tumor-shrinkage in EGFR/KRAS co-mutant disease, opening a USD 140 million micro-niche. Boehringer Ingelheim’s BI-1701963 partnered with trametinib achieved 70 % disease-control in highly mutated cohorts, while AstraZeneca’s AZD4625 plus durvalumab extended median progression-free survival to 12.8 months. These regimens raise average drug revenue per patient 32 % and elevate clinical outcomes, driving a pronounced shift in prescribing patterns: Datavagyanik projects that combination protocols will command 45 % of KRAS Inhibitors for Lung Adenocarcinoma Treatment Market share by 2029, lifting aggregate KRAS Inhibitors for Lung Adenocarcinoma Treatment demand by a further 19 000 courses annually. 

What Recent Developments Are Steering the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market?

What recent developments continue to steer the KRAS Inhibitors for Lung Adenocarcinoma Treatment Market forward? 

Recent news, pipeline, clinical trials, launches and investments 

• April 2025: Lumakras filed for first-line approval in the United States after CodeBreaK-301 survival data; PDUFA decision due Q4 2025. 

• May 2025: Krazati began a rolling submission for adjuvant therapy in resected stage IB–IIIA KRAS-mutant disease based on 68 % recurrence-risk reduction. 

• March 2025: JDQ443 received EMA PRIME designation, unlocking accelerated assessment and potential conditional EU nod by mid-2026. 

• February 2025: Revolution Medicines raised USD 350 million in a crossover round to finance a 600-patient phase III trial of RMC-6236 scheduled to start Q3 2025. 

• January 2025: Arrowhead’s ARO-KRAS secured FDA Fast Track, with a phase I read-out showing 30 % circulating-tumor-DNA clearance after two doses. 

• December 2024: Innovent’s IBI351 reached China’s Priority Review queue and attracted a USD 200 million regional licensing pact with Roche. 

• November 2024: Boehringer Ingelheim launched the SHP2 combo BI-1701963 plus BI-907828 phase II, enrolling 420 patients across 11 countries. 

• October 2024: The U.K.’s Cancer Mission announced GBP 45 million grants for KRAS synthetic-lethal screening, expanding publicly funded discovery programs. 

• September 2024: Moderna and Merck dosed first patient in the phase II trial of personalized mRNA vaccine mRNA-5671 (V941) combined with pembrolizumab following tumor resection. 

• August 2024: BridgeBio inked a USD 1.08 billion option deal with Kyowa Kirin for Asia rights to BBP-398, reinforcing cross-regional commercialization.